휴온스글로벌
Financials
Valuation Metrics
휴온스글로벌's Market Cap is ₩2570B. At end of 2025 it was ₩6482B. Ranked #674 of 2,410 in KR market (top 28%), #280 of 1,631 on KOSDAQ (top 17%), #71 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 256.99B KRW | KR#674/2,410 Sec#71/231 |
| Revenue | 846.78B KRW | KR#446/2,410 Sec#19/231 |
| Net Income | 59.47B KRW | KR#362/2,410 Sec#25/231 |
| Total Assets | 1.54T KRW | KR#366/2,410 Sec#16/231 |
| Net Assets | 1.09T KRW | KR#277/2,410 Sec#14/231 |
| Employees | 121 | KR#1,493/2,410 Sec#119/231 |
| Value | ||
| P/E | 4.32x | KR#333/2,410 Sec#11/231 |
| P/B | 0.24x | KR#246/2,410 Sec#10/231 |
| PEG | 0.02x | KR#192/2,410 Sec#7/231 |
| P/S | 0.30x | KR#648/2,410 Sec#16/231 |
| EV/EBITDA | 7.03x | KR#446/2,410 Sec#19/231 |
| FCF Yield | 18.83% | KR#384/2,410 Sec#7/231 |
| Profitability | ||
| ROE | 5.46% | KR#1,045/2,410 Sec#71/231 |
| ROA | 3.86% | KR#900/2,410 Sec#73/231 |
| Op. Margin | 8.08% | KR#653/2,410 Sec#53/231 |
| Revenue Growth | 4.07% | KR#1,253/2,410 Sec#129/231 |
| Earnings Growth | 221.67% | KR#228/2,410 Sec#13/231 |
| Financial Health | ||
| Debt Ratio | 41.41% | KR#820/2,410 Sec#95/231 |
| Total Debt | 414.25B KRW | KR#346/2,410 Sec#13/231 |
| FCF | 48.38B KRW | KR#307/2,410 Sec#17/231 |
| Cash | 190.24B KRW | KR#281/2,410 Sec#11/231 |
| Current Ratio | 1.65x | KR#1,075/2,410 Sec#120/231 |
| Net Debt/EBITDA | 3.27x | KR#922/2,410 Sec#69/231 |
| Dividend | ||
| Div. Yield | 4.32% | KR#421/2,410 Sec#15/231 |
| Div. Growth | 67.62% | KR#178/2,410 Sec#5/231 |
| Performance | ||
| 1Y Return | -62.75% | KR#2,179/2,410 Sec#208/231 |
| 1M Return | -9.98% | KR#848/2,410 Sec#90/231 |
| From 52W High | -73.53% | KR#2,147/2,410 Sec#191/231 |
| 1Y MDD | -73.04% | KR#2,083/2,410 Sec#182/231 |
| Trading | ||
| Volume | 9,411 shares | KR#1,480/2,410 Sec#148/231 |
| Trading Value | 191.2M KRW | KR#854/2,410 Sec#91/231 |
| Foreign Own. | 7.30% | KR#612/2,410 Sec#52/231 |
| Per Share | ||
| EPS | 4,697 KRW | KR#231/2,410 Sec#13/231 |
| BPS | 85,967 KRW | KR#163/2,410 Sec#9/231 |
Company Info
Established as Gwangmyeong Pharmaceutical Industries in 1965, the company transitioned into a holding company in 2016. In 2021, it physically spun off its bio business, now operating as a pure holding company. As a healthcare group with 13 affiliates, including Huons and Humedix, it boasts a diverse business portfolio spanning pharmaceutical manufacturing, fillers, arthritis treatments, and medical devices. The company generates revenue from trademark usage, management consulting, dividends, and rental income, providing management guidance through subsidiary stake acquisition and ownership. Huons Global was established in 1987 and is headquartered in Seongnam-si, Gyeonggi-do.